Alaunos Announces New Statistical Analysis of ALN1003's Liver Weight Findings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
- Liver Weight Analysis: In a 48-day diet-induced obesity mouse study, ALN1003-treated animals exhibited significantly lower liver weight after adjusting for body fat percentage compared to controls (p=0.000005), indicating that the treatment's effects are not solely explained by body fat, thus supporting further preclinical evaluation.
- Biomarker Consistency: The ALN1003-treated group showed lower HOMA-IR, an insulin-resistance-related biomarker, which remained statistically significant after body fat adjustment (p=0.0006), aligning with previous findings and suggesting potential relevance in metabolic syndrome applications.
- Adipose Endocrine Signaling: The study also revealed significantly lower leptin and higher adiponectin levels in the ALN1003-treated group, with an increased adiponectin-to-leptin ratio, consistent with the observed reduction in liver weight, further supporting the investigation of ALN1003's effects.
- Strategic Development: Alaunos CEO Holger Weis stated that these findings add important support to the ALN1003 preclinical dataset, emphasizing the necessity to continue developing the drug to evaluate its potential applications in obesity and metabolic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TCRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TCRT
About TCRT
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alaunos Announces New Statistical Analysis of ALN1003's Liver Weight Findings
- Liver Weight Analysis: In a 48-day diet-induced obesity mouse study, ALN1003-treated animals exhibited significantly lower liver weight after adjusting for body fat percentage compared to controls (p=0.000005), indicating that the treatment's effects are not solely explained by body fat, thus supporting further preclinical evaluation.
- Biomarker Consistency: The ALN1003-treated group showed lower HOMA-IR, an insulin-resistance-related biomarker, which remained statistically significant after body fat adjustment (p=0.0006), aligning with previous findings and suggesting potential relevance in metabolic syndrome applications.
- Adipose Endocrine Signaling: The study also revealed significantly lower leptin and higher adiponectin levels in the ALN1003-treated group, with an increased adiponectin-to-leptin ratio, consistent with the observed reduction in liver weight, further supporting the investigation of ALN1003's effects.
- Strategic Development: Alaunos CEO Holger Weis stated that these findings add important support to the ALN1003 preclinical dataset, emphasizing the necessity to continue developing the drug to evaluate its potential applications in obesity and metabolic diseases.
See More
Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement
- Successful Financing: Q32 Bio announced a $55 million private placement, agreeing to issue 6.725 million shares at $8.00 each, with the financing expected to close on May 28, 2026, which will provide crucial funding for the company's ongoing research, particularly for its drug candidate Bempikibart targeting severe alopecia areata.
- Clinical Trial Progress: Bempikibart is currently undergoing a Phase 2a clinical trial, with topline data expected in mid-2026; early results indicate a 16% mean reduction in SALT scores at Week 24 for treated patients, demonstrating promising efficacy that could enhance the company's market performance.
- Positive Market Reaction: Following the financing announcement, Q32 Bio's stock surged over 85%, closing at $12.85, reflecting investor confidence in the company's growth potential and likely attracting further interest in its upcoming clinical developments.
- Significant Industry Impact: The successful financing and clinical trial outcomes will bolster Q32 Bio's competitiveness in the biotechnology sector, particularly in the alopecia treatment market, potentially generating new revenue streams and strengthening its market position.
See More
Alaunos Therapeutics Reports Progress on Obesity Drug ALN1003
- Drug Candidate Efficacy: Alaunos Therapeutics' experimental obesity drug ALN1003 demonstrated weight loss and reduced food intake in mouse trials, indicating its potential in treating obesity and related metabolic disorders.
- Metabolic Health Improvements: The study showed significant improvements in insulin resistance and liver health markers in treated mice, including lower fasting insulin levels and better HOMA-IR readings, suggesting the drug's effectiveness in addressing metabolic syndrome.
- Dose Optimization Adjustments: Alaunos is optimizing the formulation of ALN1003, as some dose-related reductions in water intake affected part of the study data; however, the company remains optimistic about its future therapeutic prospects.
- Market Reaction Deterioration: Despite the positive study results, TCRT stock fell 1.66% in pre-market trading, reflecting a bearish sentiment shift in the market, with the stock down nearly 28% year-to-date.
See More
ALN1003 Shows Promising Results in Metabolic Disease Models
- Weight and Food Intake: In DIO Study 1, ALN1003-treated mice showed a peak body weight reduction of 12.9% (p<0.0001) on Day 33 and a 10.3% reduction (p<0.0001) on Day 48, indicating significant weight loss potential for obesity management.
- Body Composition Improvement: In DIO Study 2, the high-dose group exhibited a 21.9% reduction in fat as a percentage of body weight (p<0.0001) and a 17.2% increase in lean mass percentage (p<0.0001), suggesting ALN1003's potential to enhance metabolic health and reduce obesity-related risks.
- Insulin Resistance Biomarkers: DIO Study 1 revealed that ALN1003 treatment was associated with significantly lower fasting insulin levels and a decrease in HOMA-IR (p=0.0006), highlighting the drug's potential in improving insulin sensitivity.
- Liver Health Improvement: In DIO Study 1, ALN1003 significantly reduced liver weight by 43% (p<0.0001) and showed marked decreases in liver function markers such as ALT and AST compared to controls, indicating a positive impact on liver health.
See More
Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data
- Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
- Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
- Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
- Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.
See More
Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential
- Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
- Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
- Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
- Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.
See More
Alaunos Announces New Statistical Analysis of ALN1003's Liver Weight Findings
- Liver Weight Analysis: In a 48-day diet-induced obesity mouse study, ALN1003-treated animals exhibited significantly lower liver weight after adjusting for body fat percentage compared to controls (p=0.000005), indicating that the treatment's effects are not solely explained by body fat, thus supporting further preclinical evaluation.
- Biomarker Consistency: The ALN1003-treated group showed lower HOMA-IR, an insulin-resistance-related biomarker, which remained statistically significant after body fat adjustment (p=0.0006), aligning with previous findings and suggesting potential relevance in metabolic syndrome applications.
- Adipose Endocrine Signaling: The study also revealed significantly lower leptin and higher adiponectin levels in the ALN1003-treated group, with an increased adiponectin-to-leptin ratio, consistent with the observed reduction in liver weight, further supporting the investigation of ALN1003's effects.
- Strategic Development: Alaunos CEO Holger Weis stated that these findings add important support to the ALN1003 preclinical dataset, emphasizing the necessity to continue developing the drug to evaluate its potential applications in obesity and metabolic diseases.
See More
Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement
- Successful Financing: Q32 Bio announced a $55 million private placement, agreeing to issue 6.725 million shares at $8.00 each, with the financing expected to close on May 28, 2026, which will provide crucial funding for the company's ongoing research, particularly for its drug candidate Bempikibart targeting severe alopecia areata.
- Clinical Trial Progress: Bempikibart is currently undergoing a Phase 2a clinical trial, with topline data expected in mid-2026; early results indicate a 16% mean reduction in SALT scores at Week 24 for treated patients, demonstrating promising efficacy that could enhance the company's market performance.
- Positive Market Reaction: Following the financing announcement, Q32 Bio's stock surged over 85%, closing at $12.85, reflecting investor confidence in the company's growth potential and likely attracting further interest in its upcoming clinical developments.
- Significant Industry Impact: The successful financing and clinical trial outcomes will bolster Q32 Bio's competitiveness in the biotechnology sector, particularly in the alopecia treatment market, potentially generating new revenue streams and strengthening its market position.
See More
Alaunos Therapeutics Reports Progress on Obesity Drug ALN1003
- Drug Candidate Efficacy: Alaunos Therapeutics' experimental obesity drug ALN1003 demonstrated weight loss and reduced food intake in mouse trials, indicating its potential in treating obesity and related metabolic disorders.
- Metabolic Health Improvements: The study showed significant improvements in insulin resistance and liver health markers in treated mice, including lower fasting insulin levels and better HOMA-IR readings, suggesting the drug's effectiveness in addressing metabolic syndrome.
- Dose Optimization Adjustments: Alaunos is optimizing the formulation of ALN1003, as some dose-related reductions in water intake affected part of the study data; however, the company remains optimistic about its future therapeutic prospects.
- Market Reaction Deterioration: Despite the positive study results, TCRT stock fell 1.66% in pre-market trading, reflecting a bearish sentiment shift in the market, with the stock down nearly 28% year-to-date.
See More
ALN1003 Shows Promising Results in Metabolic Disease Models
- Weight and Food Intake: In DIO Study 1, ALN1003-treated mice showed a peak body weight reduction of 12.9% (p<0.0001) on Day 33 and a 10.3% reduction (p<0.0001) on Day 48, indicating significant weight loss potential for obesity management.
- Body Composition Improvement: In DIO Study 2, the high-dose group exhibited a 21.9% reduction in fat as a percentage of body weight (p<0.0001) and a 17.2% increase in lean mass percentage (p<0.0001), suggesting ALN1003's potential to enhance metabolic health and reduce obesity-related risks.
- Insulin Resistance Biomarkers: DIO Study 1 revealed that ALN1003 treatment was associated with significantly lower fasting insulin levels and a decrease in HOMA-IR (p=0.0006), highlighting the drug's potential in improving insulin sensitivity.
- Liver Health Improvement: In DIO Study 1, ALN1003 significantly reduced liver weight by 43% (p<0.0001) and showed marked decreases in liver function markers such as ALT and AST compared to controls, indicating a positive impact on liver health.
See More
Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data
- Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
- Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
- Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
- Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.
See More
Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential
- Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
- Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
- Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
- Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.
See More
